vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v12i1.555vsp-367Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESЭФФЕКТИВНОСТЬ ИММУНОКОРРЕКЦИИ С ПОМОЩЬЮ СИНТЕТИЧЕСКОГО ДИПЕПТИДА ПРИ ПИЕЛОНЕФРИТЕ У ДЕТЕЙEFFICACY OF IMMUNOCORRECTIVE TREATMENT WITH SYNTHETIC DIPEPTIDE IN CHILDREN WITH PYELONEPHRITISКирилловВ. И.KirillovV. I.neonatepearl@yandex.ruЗайцеваО. В.ZaitsevaO. V.neonatepearl@yandex.ruБогдановаН. А.BogdanovaN. A.neonatepearl@yandex.ruМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian Federation201303022013121Вопросы современной педиатрии2429Copyright © Кириллов В.И., Зайцева О.В., Богданова Н.А., 20132013Кириллов В.И., Зайцева О.В., Богданова Н.А.Kirillov V.I., Zaitseva O.V., Bogdanova N.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/367

Результаты открытого контролируемого проспективного клинико-иммунологического исследования свидетельствуют о том, что включение в комплексную терапию пиелонефрита у детей пидотимода (n =30) достоверно чаще приводит к снижению вероятности и кратности обострений заболевания на протяжении 6 мес после окончания лечения по сравнению с пациентами, находившимися только на антибактериальной терапии (n =20 При обострении у больных, получавших данный препарат, сокращалась продолжительность и длительность этиотропной терапии для купирования активных проявлений мочевой инфекции. Иммунологический мониторинг цитокинового профиля мочи во время применения пидотимода продемонстрировал признаки преобладания активации Т хелперов 1-го типа (повышение соотношения интерферон γ/интерлейкин 10), а также снижение содержания гранулоцитарно-макрофагального колониестимулирующего фактора, что, по-видимому, обусловливает отсроченное влияние препарата на характер течения инфекции мочевой системы.

 

The results of the open controlled prospective clinical and immunological trial indicate that including of pidotimod into the complex therapy of pyelonephritis in children (n=30) lead to reliable decrease of recurrence risk and frequency during 6 months after treatment withdrawal in comparison with children receiving antibacterial monotherapy (n=20). The duration of etiotropic treatment for arresting of the active manifestations of urinary tract infection was lower in patients who were administered the afore-mentioned drug. Immunological monitoring of the urine cytokine status during pidotimod treatment showed that there were signs of T helper 1 cells activation predominance (increase in interferon/interleukin 10 ratio), as well as decrease in granulocyte macrophage colony-stimulating factor concentration, which seems to cause the delayed influence of the drug on the course of urinary tract infection.

 

пидотимодпиелонефритцитокиныchildrenpidotimodpyelonephritiscytokinesReferencesKaraulov A. V. Immunological rehabilitation in diseases of visceral organs. Doctoral thesis. Moscow. 1987.Karaulov A. V. Immunological rehabilitation in diseases of visceral organs. Doctoral thesis. Moscow. 1987.Kuznetsov V.P, Belyayev D. L., Babayants A. A. Conception of immunocorrection in patients with multifactor immunodeficiency, infectious and oncological diseases. Journal of microbiology, epidemiology and immunobilolgy. 1996; 5: Pp. 104–110.Kuznetsov V.P, Belyayev D. L., Babayants A. A. Conception of immunocorrection in patients with multifactor immunodeficiency, infectious and oncological diseases. Journal of microbiology, epidemiology and immunobilolgy. 1996; 5: Pp. 104–110.Khaitov R. M., Pinegin B. V. Main principles of immunomodulatory therapy. Allergy, asthma and clinical immunology. 2000; 1: Pp. 9–16.Khaitov R. M., Pinegin B. V. Main principles of immunomodulatory therapy. Allergy, asthma and clinical immunology. 2000; 1: Pp. 9–16.Kirillov V. I. Immunological disorders in patients with infections of urinary system and methods of their correction. In the book: Infection of urinary system in children. Moscow: M-Art. 2011. Pp. 102–132.Kirillov V. I. Immunological disorders in patients with infections of urinary system and methods of their correction. In the book: Infection of urinary system in children. Moscow: M-Art. 2011. Pp. 102–132.Korovina N. A., Dlin V. V., Ignatova M. S. Microbial inflammatory diseases of organs of urinary system. Children’s nephrology. Guideline for doctors. Edited by Ignatov M. S. Moscow: MIA. 2011. Pp. 456–479.Korovina N. A., Dlin V. V., Ignatova M. S. Microbial inflammatory diseases of organs of urinary system. Children’s nephrology. Guideline for doctors. Edited by Ignatov M. S. Moscow: MIA. 2011. Pp. 456–479.Korovina N. A., Burtsev V. I., Isachenko V. P., Tikhonov Ye. K. Influence of prodigiosanum in several clinical and immunological tests in children with pyelonephritis. Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1976; 2: pp. 72–76.Korovina N. A., Burtsev V. I., Isachenko V. P., Tikhonov Ye. K. Influence of prodigiosanum in several clinical and immunological tests in children with pyelonephritis. Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1976; 2: pp. 72–76.Kirillov V. I., Tebloyeva L. T., Arion V.Ya. et al. Short-term and long-term results of Tactivinum in children with acute and chronic pyelonephritis. Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1994; 2: pp48–52.Kirillov V. I., Tebloyeva L. T., Arion V.Ya. et al. Short-term and long-term results of Tactivinum in children with acute and chronic pyelonephritis. Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1994; 2: pp48–52.Korovina N. A., Repina Ye. A. Viferon in patients with renal diseases. Russian bulletin of perinatology and Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1998; 3: pp. 30–33.Korovina N. A., Repina Ye. A. Viferon in patients with renal diseases. Russian bulletin of perinatology and Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1998; 3: pp. 30–33.Tebloyeva L. T., Kirillov V. I., Runenko V. I., Yefremova I. I. Clinical efficacy of Imunofan in treatment of pyelonephritis in children. Materials of II Convent of Pediatricians-Nephrologists of Russia. Moscow. 2000. 35 pp.Tebloyeva L. T., Kirillov V. I., Runenko V. I., Yefremova I. I. Clinical efficacy of Imunofan in treatment of pyelonephritis in children. Materials of II Convent of Pediatricians-Nephrologists of Russia. Moscow. 2000. 35 pp.Lykina Ye. V., Zakharova I. N., Al-Makrami Ali. Effect of licopid in children with pyelonephritis. Materials of III Convent of PediatriciansNephrologists of Russia. St.-Petersburg. 2003. 129 pp.Lykina Ye. V., Zakharova I. N., Al-Makrami Ali. Effect of licopid in children with pyelonephritis. Materials of III Convent of PediatriciansNephrologists of Russia. St.-Petersburg. 2003. 129 pp.Saphina A. I. Use of polyoxidonium in complex therapy of pyelonephritis in children. Nephrology and dialysis. 2005; 7: pp. 468–473.Saphina A. I. Use of polyoxidonium in complex therapy of pyelonephritis in children. Nephrology and dialysis. 2005; 7: pp. 468–473.Coppi G., Falcone A., Manzardo S. Protective effects of pidotimod against experimental bacterial infections in mice. Arztneimittel Forschung. 1994; 44: 1417–1421.Coppi G., Falcone A., Manzardo S. Protective effects of pidotimod against experimental bacterial infections in mice. Arztneimittel Forschung. 1994; 44: 1417–1421.Gourgiotis D., Papandopoulos N. G., Bossios A. Immune modulator pidotimod decreases in vitro expression of CD 30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J. Asthma. 2004; 41: 285–287.Gourgiotis D., Papandopoulos N. G., Bossios A. Immune modulator pidotimod decreases in vitro expression of CD 30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J. Asthma. 2004; 41: 285–287.Tebloyeva L. T., Kirillov V. I. On the question of topical diagnostics and treatment of urinary tract infections in children. Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1999; 1: pp. 93–97.Tebloyeva L. T., Kirillov V. I. On the question of topical diagnostics and treatment of urinary tract infections in children. Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1999; 1: pp. 93–97.Antimicrobial therapy and prophylaxis of kidneys, urinary tract and male reproductive organs. Russian National Recommendations. Moscow. 2012. 64 pp.Antimicrobial therapy and prophylaxis of kidneys, urinary tract and male reproductive organs. Russian National Recommendations. Moscow. 2012. 64 pp.Kovalchuk L. V., Gankovskaya L. V., Rubakova E. I. Cytokines system. Moscow: RSMU. 1999. 77 pp.Kovalchuk L. V., Gankovskaya L. V., Rubakova E. I. Cytokines system. Moscow: RSMU. 1999. 77 pp.Kuznetsov V. P., Markelova Ye. V., Kolesnikova N. V. et al. Immuno correcting treatment in patients with infections — questions of strategy. In the book: Successes of clinical immunology and allergology. Edited by A. V. Karaulov. Moscow: Regional department of Russian Academy of Natural Sciences. 2001. Pp. 199–229.Kuznetsov V. P., Markelova Ye. V., Kolesnikova N. V. et al. Immuno correcting treatment in patients with infections — questions of strategy. In the book: Successes of clinical immunology and allergology. Edited by A. V. Karaulov. Moscow: Regional department of Russian Academy of Natural Sciences. 2001. Pp. 199–229.Karaulov A. V., Kokushkov D. V. Pidotimod: mechanism of action and efficacy against respiratory infections. Children’s pharmacology. 2008; 5: pp. 25–29.Karaulov A. V., Kokushkov D. V. Pidotimod: mechanism of action and efficacy against respiratory infections. Children’s pharmacology. 2008; 5: pp. 25–29.Clemente E., Solli R., Mei V. et al. Therapeutic efficacy and safety of pidotimod in the treatment of urinary tract infection in children. Arztneimittel Forschung. 1999; 44: 1490–1494.Clemente E., Solli R., Mei V. et al. Therapeutic efficacy and safety of pidotimod in the treatment of urinary tract infection in children. Arztneimittel Forschung. 1999; 44: 1490–1494.Sitnikova V. P., Pashkova Yu. V., Remizov B. A. Diagnostical value of tests of cytokines level in children with nephropathies. Х Russian Congress of Children’s Nephrology. Medical bulletin of South of Russia. 2012. Pp. 83–84.Sitnikova V. P., Pashkova Yu. V., Remizov B. A. Diagnostical value of tests of cytokines level in children with nephropathies. Х Russian Congress of Children’s Nephrology. Medical bulletin of South of Russia. 2012. Pp. 83–84.Agace W., Hedges S., Andersson V. et al. Selective cytokine production by epithelial cells following exposure to Escherichia coli. Infect. Immunol. 1993; 61: 602–609.Agace W., Hedges S., Andersson V. et al. Selective cytokine production by epithelial cells following exposure to Escherichia coli. Infect. Immunol. 1993; 61: 602–609.Ni A. N., Bykova O. G. Dynamics of TNF level in urine of children with chronic pyelonephritis. Х Russian Congress of Children’s Nephrology. Medical bulletin of South of Russia. 2012. Pp. 64–65.Ni A. N., Bykova O. G. Dynamics of TNF level in urine of children with chronic pyelonephritis. Х Russian Congress of Children’s Nephrology. Medical bulletin of South of Russia. 2012. Pp. 64–65.Coppi G., Manzardo S. Experimental immunological screening tests of pidotimod. Arztneimittel Forschung. 1999; 44: 1411–1416.Coppi G., Manzardo S. Experimental immunological screening tests of pidotimod. Arztneimittel Forschung. 1999; 44: 1411–1416.Taramelli D., Malabarba M. G., Basilio N. et al. Effects of pidotimod on macrophage functions in methylprednisolone-treated mice. Arztneimittel Forschung. 1999; 44: 1425–1430.Taramelli D., Malabarba M. G., Basilio N. et al. Effects of pidotimod on macrophage functions in methylprednisolone-treated mice. Arztneimittel Forschung. 1999; 44: 1425–1430.

The authors declare that there are no conflicts of interest present.